רווח למניה בשנים עשר החודשים האחרונים: Tempest Therapeutics Inc (TPST)

Tempest Therapeutics research center resources are fully deployed in the development of anti-tumor agents. The company's TTM net income per share reflects the dynamics of these expenditures, where the -4.48 level serves as a critical benchmark. However, a high dependency on the outcome of liver cancer treatment trials and the risk of rapid capital depletion create significant instability for the business.

Investors seek a balance between asset value and business quality. This metric reflects the aggregate net income per share over the last four quarters, combining data from 10-K and 10-Q filings. For the biotech company Tempest Therapeutics (TPST), which develops selective PPAR inhibitors, this indicator demonstrates the efficiency of R&D expenditures. The net income per share trend over the last four quarters allows for the timely identification of a fundamental reversal.